Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer

Authors

DOI:

https://doi.org/10.15587/2519-4798.2021.228185

Keywords:

Non-muscle invasive bladder cancer, hyperthermic intravesical chemotherapy, BCG therapy

Abstract

The aim: to compare disease-free survival time (DFS) in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant hyperthermic intravesical chemotherapy and standard BCG therapy.

Materials and methods: patients were divided into 2 groups. Group 1 (control) included patients who received adjuvant therapy after TURB with BCG vaccine (BCG therapy group; n=50), group 2 (study group) included patients (HIVEC® therapy group; n=46 ), who received adjuvant intravesical chemotherapy using a Combat BRS HIVEC® device for local hyperthermia.

Results: median follow-up was 23 months (range 4 - 36). Tumor recurrence was reported in 19 patients receiving intravesical BCG therapy and in 8 patients receiving intravesical hyperthermic chemotherapy. The incidence of DFS in patients receiving chemohyperthermy was statistically higher than in patients receiving BCG therapy (log-rank test result: p=0.029).

Conclusions: The method of hyperthermic intravesical chemotherapy significantly increased the 2-year disease-free survival rate - 82.6 % versus 62 % BCG therapy group (p=0.025). Its use in the future will allow increasing the frequency of organ-preserving treatment of patients with primary and recurrent muscular-non-invasive bladder tumors

Author Biography

Roman Chystiakov, Odessa National Medical University

Assistant

Department of Radiation Diagnostic, Therapy and Oncology

References

  1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. doi: http://doi.org/10.3322/caac.21660
  2. Fedorenko, Z. P., Hulak, L. O., Mykhailovych, Yu. Y., Horokh, Ye. L., Ryzhov, A. Yu., Sumkina, O. V., Kutsenko, L. B. (2020). Rak v Ukraini, 2018–2019. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten Natsionalnoho kantser-reiestru Ukrainy, 21, 101.
  3. Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P. et. al. (2013). Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63 (2), 234–241. doi: http://doi.org/10.1016/j.eururo.2012.07.033
  4. Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M., Jemal, A. (2014). International Variations in Bladder Cancer Incidence and Mortality. European Urology, 66 (1), 59–73. doi: http://doi.org/10.1016/j.eururo.2013.10.001
  5. Compérat, E., Larré, S., Roupret, M., Neuzillet, Y., Pignot, G., Quintens, H. et. al. (2015). Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Archiv, 466 (5), 589–594. doi: http://doi.org/10.1007/s00428-015-1739-2
  6. Cambier, S., Sylvester, R. J., Collette, L., Gontero, P., Brausi, M. A., van Andel, G. et. al. (2016). EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. European Urology, 69 (1), 60–69. doi: http://doi.org/10.1016/j.eururo.2016.01.055
  7. Xylinas, E., Kent, M., Kluth, L., Pycha, A., Comploj, E., Svatek, R. S. et. al. (2013). Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. British Journal of Cancer, 109 (6), 1460–1466. doi: http://doi.org/10.1038/bjc.2013.372
  8. Sylvester, R. J., Oosterlinck, W., Holmang, S., Sydes, M. R., Birtle, A., Gudjonsson, S. et. al. (2016). Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? European Urology, 69 (2), 231–244. doi: http://doi.org/10.1016/j.eururo.2015.05.050
  9. Malmström, P.-U., Sylvester, R. J., Crawford, D. E., Friedrich, M., Krege, S., Rintala, E. et. al. (2009). An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer. European Urology, 56 (2), 247–256. doi: http://doi.org/10.1016/j.eururo.2009.04.038
  10. Babjuk, M., Burger, M., Compérat, E., Gontero, P., Mostafid, A. H., Palou, J. et. al. (2020). EAU Guideline Non-Muscle-Invasive Bladder Cancer. Proceedings of the EAU Annual Congress Amsterdam 2020. Virtual Congress. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ Last accessed: 26.08.2020
  11. Hautmann, R. E., de Petriconi, R. C., Volkmer, B. G. (2010). Lessons Learned From 1,000 Neobladders: The 90-Day Complication Rate. Journal of Urology, 184 (3), 990–994. doi: http://doi.org/10.1016/j.juro.2010.05.037
  12. Parker, W. P., Smelser, W., Lee, E. K., Habermann, E. B., Thapa, P., Zaid, H. B. et. al. (2018). Utilization and Outcomes of Radical Cystectomy for High-grade Non–muscle-invasive Bladder Cancer in Elderly Patients. Clinical Genitourinary Cancer, 16 (1), e79–e97. doi: http://doi.org/10.1016/j.clgc.2017.07.011
  13. Van Valenberg, H.; Colombo, R.; Witjes, F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int. J. Hyperth. 2016, 32, 351–362. https://doi.org/10.3109/02656736.2016.1140232
  14. Mantso, T., Goussetis, G., Franco, R., Botaitis, S., Pappa, A., Panayiotidis, M. (2016). Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies. Seminars in Cancer Biology, 37-38, 96–105. doi: http://doi.org/10.1016/j.semcancer.2016.03.004
  15. Tan, W. S., Kelly, J. D. (2018). Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology, 15 (11), 667–685. doi: http://doi.org/10.1038/s41585-018-0092-z
  16. Van Valenberg, F. J. P., van der Heijden, A. G., Lammers, R. J. M., Falke, J., Arends, T. J. H., Oosterwijk, E., Witjes, J. A. (2017). Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. International Journal of Hyperthermia, 34 (7), 988–993. doi: http://doi.org/10.1080/02656736.2017.1406618
  17. Kоstyev, F. І., Bondar, О. V., Chystiakov, R. S., Lysenko, V. V. (2020). Impact of adjuvant intrabladder therapy on quality of life in patients, suffering musculo-noninvasive cancer of the bladder. Klinicheskaia Khirurgiia, 87 (7-8), 47–52. doi: http://doi.org/10.26779/2522-1396.2020.7-8.47
  18. Tan, W. S., Panchal, A., Buckley, L., Devall, A. J., Loubière, L. S., Pope, A. M. et. al. (2019). Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology, 75 (1), 63–71. doi: http://doi.org/10.1016/j.eururo.2019.01.030
  19. Brummelhuis, I. S. G., Wimper, Y., Witjes-van Os, H. G. J. M., Arends, T. J. H., van der Heijden, A. G., Witjes, J. A. (2021). Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers, 13 (3), 377. doi: http://doi.org/10.3390/cancers13030377

Downloads

Published

2021-04-05

How to Cite

Chystiakov, R. (2021). Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer. ScienceRise: Medical Science, (2(41), 22–27. https://doi.org/10.15587/2519-4798.2021.228185

Issue

No. 2(41) (2021)

Section

Medical Science

License

Copyright (c) 2021 Roman Chystiakov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.